Atrasentan hydrochloride

Atrasentan Hydrochloride is a highly potent and selective endothelin A (ETA) receptor antagonist originally developed at Abbott Laboratories (ABT-627; A-147627) for the treatment of metastatic hormone-refractory prostate cancer. Atrasentan Hydrochloride works by selectively blocking ETA receptors, thereby reducing vascular resistance, inhibiting pathological tissue remodeling, and modulating endothelin-driven signaling pathways. Beyond oncology, Atrasentan Hydrochloride has been extensively investigated in clinical trials for diabetic nephropathy and cardiovascular diseases. As a hydrochloride salt of the active pharmaceutical ingredient, Atrasentan Hydrochloride offers improved physicochemical properties including enhanced stability and solubility, facilitating both formulation development and analytical handling in pharmaceutical research contexts.

Product Parameters

---

Parameter	Specification
Product Name	Atrasentan Hydrochloride
CAS Number	195733-43-8
Molecular Formula	C₂₉H₃₉ClN₂O₆
Molecular Weight	547.08 g/mol
Appearance	Off-white to gray powder
Storage Condition	under inert gas (nitrogen or Argon) at 2-8°C

Bioactivity

---

Atrazenamide hydrochloride (ABT-627 hydrochloride) is an effective selective endothelin A receptor antagonist that inhibits ETA activity with an IC50 value of 0.0551 nM.

 

Target

---

IC50: 0.055 nM (ETA)

 

Why Cosperpharm?

---

When your endothelin receptor antagonist research program or oncology drug development project requires high-purity reference standards and research intermediates, Cosperpharm delivers Atrasentan Hydrochloride with the quality, documentation, and supply flexibility that pharmaceutical researchers demand.

 

Precise stereochemical integrity. The three chiral centers of Atrasentan Hydrochloride (2R, 3R, 4S) are critical to its picomolar ETA receptor affinity. Any stereochemical impurity compromises receptor binding and biological activity. Cosperpharm's analytical release protocol includes chiral HPLC verification to confirm the correct stereoisomeric composition — because your pharmacological data depends on the stereochemical purity of this compound.

 

Documentation that supports your research. Every shipment includes a Certificate of Analysis (COA) with batch‑specific HPLC purity, chromatographic traceability, and identity confirmation by FTIR, NMR, and mass spectrometry. Custom quality documentation is available upon request for regulatory submissions.

 

Flexible supply for all research stages. Cosperpharm supplies Atrasentan Hydrochloride across the full range of applications — from milligram quantities for screening assays and receptor binding studies, to gram-scale batches for in vivo pharmacology and formulation development.

 

Technical support from experienced chemists. Our team can advise on solubility optimization, formulation compatibility, and analytical method development for Atrasentan Hydrochloride — because we understand the complexities of working with this structurally demanding molecule.

 

Global reach with transparent pricing. Cosperpharm ships to pharmaceutical companies, CROs, and research institutions worldwide, with full customs documentation included.

 

Contact Us

---

Whether you need Atrasentan Hydrochloride for receptor binding studies, oncology research, or as a reference standard for analytical method development, Cosperpharm is your trusted partner. Our team is ready to support your research with high-quality products, comprehensive documentation, and responsive technical service. Reach out today — we‘re here to help you move your project forward.